Fund managers back market darling Telix Pharmaceuticals

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

España Noticias Noticias

España Últimas Noticias,España Titulares

A bevvy of healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.

Shares in Telix Pharmaceuticals have surged more than tenfold in five years as a record June quarter of sales supports phenomenal investor interest in the cancer diagnostic and treatment business.

Antares is among Australian equities managers such as Platinum Asset Management, Perennial Partners, Fidelity, Acorn Capital, and Wilson Asset Management that own Telix shares. “We still think shares have further upside,” said Mr Hamilton. “I think that first [June] quarter of commercial sales in Illucix show it’s a great product. It entered the market and got very good awareness of PSMA imaging.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 2. in ES
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

tommyr345 still a puppet for asxlongtail Only biotech Tom covers strangely, share price is the same as last time you wrote a puff piece for him 🤡

España Últimas Noticias, España Titulares